Eli Lilly and Company (NYSE:LLY) Position Lessened by SkyOak Wealth LLC

SkyOak Wealth LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.4% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 24,439 shares of the company’s stock after selling 873 shares during the period. Eli Lilly and Company accounts for approximately 3.7% of SkyOak Wealth LLC’s portfolio, making the stock its 6th largest holding. SkyOak Wealth LLC’s holdings in Eli Lilly and Company were worth $14,246,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Thompson Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter worth $27,000. Retirement Group LLC increased its position in Eli Lilly and Company by 159.1% during the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after purchasing an additional 35 shares in the last quarter. Cornerstone Planning Group LLC acquired a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $33,000. Legacy Financial Group LLC acquired a new stake in shares of Eli Lilly and Company in the third quarter worth $35,000. Finally, Optiver Holding B.V. acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at $36,000. Hedge funds and other institutional investors own 81.38% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 1,180 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $645.60, for a total value of $761,808.00. Following the transaction, the insider now directly owns 99,542,630 shares in the company, valued at approximately $64,264,721,928. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have sold 195,055 shares of company stock valued at $125,254,657. 0.13% of the stock is currently owned by insiders.

Analysts Set New Price Targets

LLY has been the subject of a number of recent research reports. BMO Capital Markets increased their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $815.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, February 20th. Truist Financial reaffirmed a “buy” rating and set a $850.00 price target on shares of Eli Lilly and Company in a report on Friday. Wells Fargo & Company raised their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Finally, JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $689.52.

Eli Lilly and Company Stock Performance

LLY stock traded up $0.04 during midday trading on Friday, hitting $770.30. The stock had a trading volume of 1,979,787 shares, compared to its average volume of 3,298,234. The firm has a market capitalization of $731.91 billion, a price-to-earnings ratio of 132.86, a P/E/G ratio of 1.70 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The stock has a 50-day simple moving average of $720.00 and a 200 day simple moving average of $630.77. Eli Lilly and Company has a 52 week low of $323.26 and a 52 week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period in the prior year, the company posted $2.09 EPS. The company’s revenue was up 28.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Eli Lilly and Company will post 12.42 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.